{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:14:33Z","timestamp":1753737273671,"version":"3.37.3"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"Supplement_L","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diabetes and chronic kidney disease (CKD) are important comorbidities in patients with heart failure (HF) that can complicate the clinical management and have major implications for morbidity and mortality. In addition, the presence of these comorbidities, particularly advanced CKD, is a limitation for the implementation of guideline-directed therapies in patients with HF with reduced ejection fraction (HFrEF). Though clinical trials in patients with HFrEF trials included varying percentages of patients with diabetes and\/or CKD, patients with advanced CKD have been excluded in most HF studies. Thus, management recommendations for these patients often have to be extrapolated from subgroup analyses. This article summarizes pathophysiological aspects of the interaction of HFrEF, CKD, and diabetes and addresses clinical aspects for the screening of these comorbidities. Moreover, current treatment options for patients with HFrEF and CKD and\/or diabetes are discussed and novel strategies such as the use of the selective mineralocorticoid receptor antagonist Finerenone are addressed.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suac114","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T21:32:42Z","timestamp":1671485562000},"page":"L29-L37","source":"Crossref","is-referenced-by-count":1,"title":["Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University , Pauwelsstra\u00dfe 30, D-52074 Aachen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Y Y","family":"Cheng","sequence":"additional","affiliation":[{"name":"Trillium Health Partners and Unity Health Toronto, Department of Medicine, University of Toronto , 507-2300 Eglinton Avenue West, Mississauga, Ontario L5M 2V8 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Indiana University School of Medicine and Richard L. Roudebush VA Medical Center , 1481 West 10th St, 111N Indianapolis, IN 46202 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Cardiology Advanced Heart Failure & Transplantation, Duke Clinical Research Institute , 40 Duke Medicine CircleClinic 2K Room 2250, Orange Zone Durham, NC 27710 , USA"},{"name":"Division of Cardiology, Duke University School of Medicine , 40 Duke Medicine CircleClinic 2K Room 2250, Orange Zone Durham, NC 27710 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Abuhantash","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Jordan , Amman PO Box 815447 , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2023021409525229300_suac114-B1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"2023021409525229300_suac114-B2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2023021409525229300_suac114-B3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","article-title":"Management of heart failure in advancing CKD: core curriculum 2018","volume":"72","author":"House","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2023021409525229300_suac114-B4","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to Pre-diabetes Mellitus and diabetes Mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail."},{"key":"2023021409525229300_suac114-B5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2014.07.003","article-title":"Basic science: pathophysiology: the cardiorenal metabolic syndrome","volume":"8","author":"Whaley-Connell","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2023021409525229300_suac114-B7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/ndt\/gfv041","article-title":"The vulnerable patient with chronic kidney disease","volume":"31","author":"Schlieper","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2023021409525229300_suac114-B8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/CIRCRESAHA.116.310078","article-title":"Evolving concepts of myocardial energy metabolism: more than just fats and carbohydrates","volume":"119","author":"Lopaschuk","year":"2016","journal-title":"Circ Res"},{"key":"2023021409525229300_suac114-B9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B10","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"key":"2023021409525229300_suac114-B11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes Status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B12","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2023021409525229300_suac114-B13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-Normal albuminuria and risk of heart failure in the community","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2023021409525229300_suac114-B14","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B15","doi-asserted-by":"crossref","first-page":"P387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"2023021409525229300_suac114-B16","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023021409525229300_suac114-B17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2023021409525229300_suac114-B18","first-page":"14","article-title":"Diabetes Canada 2018 clinical practice guidelines: key messages for family physicians caring for patients living with type 2 diabetes","volume":"65","author":"Ivers","year":"2019","journal-title":"Can Fam Physician"},{"key":"2023021409525229300_suac114-B19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2023021409525229300_suac114-B20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (st vincent's screening TO prevent heart failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2023021409525229300_suac114-B21","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","article-title":"Clinical implications of echocardiographic phenotypes of patients with diabetes Mellitus","volume":"70","author":"Ernande","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B22","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"2023021409525229300_suac114-B23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"2023021409525229300_suac114-B24","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023021409525229300_suac114-B25","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U. S. Remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"key":"2023021409525229300_suac114-B26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023021409525229300_suac114-B27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American college of cardiology solution set oversight committee","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0002-8703(03)00403-4","article-title":"Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials","volume":"146","author":"Haas","year":"2003","journal-title":"Am Heart J"},{"key":"2023021409525229300_suac114-B29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B35","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"Empagliflozin and cerebrovascular events in patients with type 2 diabetes Mellitus at high cardiovascular risk","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"key":"2023021409525229300_suac114-B36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.118.037599","article-title":"Primary prevention of heart failure in patients with type 2 diabetes Mellitus","volume":"139","author":"Greene","year":"2019","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B38","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B40","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 Inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2023021409525229300_suac114-B41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2023021409525229300_suac114-B43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2021","journal-title":"Diabetes Care"},{"key":"2023021409525229300_suac114-B44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the Spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (\u201cdip\u201d) in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B46","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized aldactone evaluation study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2023021409525229300_suac114-B48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2023021409525229300_suac114-B49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023021409525229300_suac114-B50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2023021409525229300_suac114-B51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2023021409525229300_suac114-B52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the heart failure association of the European society of cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023021409525229300_suac114-B53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on Major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2018","journal-title":"JAMA"},{"key":"2023021409525229300_suac114-B56","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B57","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2023021409525229300_suac114-B58","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"2023021409525229300_suac114-B59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2023021409525229300_suac114-B60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2023021409525229300_suac114-B61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. Eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2023021409525229300_suac114-B62","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B63","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023021409525229300_suac114-B64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023021409525229300_suac114-B65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_L\/L29\/49174690\/suac114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_L\/L29\/49174690\/suac114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:28:50Z","timestamp":1676374130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_L\/L29\/6933308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":65,"journal-issue":{"issue":"Supplement_L","published-online":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2022,12,19]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac114","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"type":"print","value":"1520-765X"},{"type":"electronic","value":"1554-2815"}],"subject":[],"published-other":{"date-parts":[[2022,12,27]]},"published":{"date-parts":[[2022,12,19]]}}}